Even though improved diagnostic efficacy during single NEP inhibition has been recently confirmed for a biodegradable radiolabeled gastrin analog in medullary thyroid carcinoma patients [30,31,32], the clinical translation of this concept in the case of NT radioligands would require dual ACE/NEP inhibition. This evidence concerns the gene MME and medullary thyroid gland carcinoma.